Domainex spoke with PharmaTelevision in December 2014 to explain:

• the collaboration with ZoBio and the combination of Domainex's CDH technology with ZoBio's state-of-the-art NMR capabilities
• Domainex's work on behalf of Auspherix
• Domainex's future investment round plans
• How Domainex operates a hybrid business model to generate revenues and reduce burn rate
• How Domainex plans to partner its TBK1/IKKe programme for the treatment of inflammatory diseases

Get the Flash Player to see this video.